Impact of multidrug resistance-related protein 3 gene silenced by siRNA on the drug resistance of liver cancer cells

doi:10.3877/cma.j.issn.2095-3232.2014.03.011

Abstract

Abstract:

Objective

To observe the impact of multidrug resistance-related protein (MRP) 3 gene silenced by small interfering RNA (siRNA) (MRP3-siRNA) on the drug resistance of primary liver cancer cells.

Methods

The drug resistance cell lines HepG2/Adriamycin(ADM) were developed by exposing parental cells to stepwise increasing concentrations of ADM and then MRP3-siRNAs were transfected in HepG2/ADM cells with lipofectamine 2000 liposomes. Three groups were assigned: HepG2 cell group (control group), HepG2/ADM cell group (resistance group) and MRP3-siRNA transfected HepG2/ADM cell group (interference group). The MRP3 mRNA contents of 3 groups were measured by real-time fluorescent quantitative polymerase chain reaction (PCR). The expression of MRP3 protein was detected by Western blot. The 50% inhibitory concentrations (IC₅₀) of ADM, fluorouracil (5-FU), vincristine, oxaliplatin were determined by methyl thiazolyl tetrazolium (MTT) and the drug resistance indexes (RI) were calculated. The experimental data of 3 groups were compared by one-way analysis of variance, while pairwise comparisons were conducted using LSD-t or t test.

Results

The mean of MRP3 mRNA content in resistance group (5.16±0.31) was significantly higher than those in control group (3.08±0.27) and interference group (2.85±0.23) (LSD-t=8.765, 10.363; P<0.05). The MRP3 protein content in resistance group (21 063±274) was significantly higher than those in control group (14 476±217) and interference group (6 660±153) (LSD-t=21.836, 79.578; P<0.05). The RI of ADM, 5-FU,vincristine, oxaliplatin in resistance group were 14.40±0.31, 26.68±0.22, 28.70±0.49, 20.23±0.54, and were 3.55±0.16, 9.60±0.27, 2.11±0.17, 3.15±0.13 respectively in interference group. The RI in interference group were significantly lower than those in resistance group (t=53.873, 84.933, 88.811, 53.258; P<0.05).

Conclusions

MRP3 gene of liver cancer cells silenced by siRNA can improve the cells' sensitivity to chemotherapy drugs and reverse its chemotherapy drug resistance.

Key words: Liver neoplasms, experimental, RNA interference, Multidrug resistance-associated proteins

Zheng Su, Bo Liu, Jianping Liu, Huayao Zhang, Zejian Lyu, Ziliang Cheng. Impact of multidrug resistance-related protein 3 gene silenced by siRNA on the drug resistance of liver cancer cells[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2014, 03(03): 174-177.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2014.03.011

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2014/V03/I03/174

Figures/Tables 2

References 16

[1]	吴孟超．肝癌在中国[J/CD]．中华肝脏外科手术学电子杂志，2012, 1(1):3-4.
[2]	颜见，姚志成，钟跃思，等．肝细胞肝癌840例临床分析[J/CD]．中华肝脏外科手术学电子杂志，2012, 1(1):33-37.
[3]	Wang CF, Wang YQ, Huang FZ, et al. Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma[J]. J Int Med Res, 2013, 41(4):964-974.
[4]	Slot AJ, Molinski SV, Cole SP. Mammalian multidrug-resistance proteins (MRPs)[J]. Essays Biochem, 2011, 50(1):179-207.
[5]	Korita PV, Wakai T, Shirai Y, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma[J]. Oncol Rep, 2010, 23(4):965-972.
[6]	Folmer Y, Schneider M, Blum HE, et al. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs[J]. Cancer Gene Ther, 2007, 14(11):875-884.
[7]	汪洋，褚忠华，刘建平，等．小干扰RNA调控多药耐药相关蛋白1基因对SMMC7721肝癌细胞株多药耐药性的影响[J]．中华实验外科杂志，2013, 30(9):1889-1892.
[8]	Seo S, Hatano E, Higashi T, et al. P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro[J]. Int J Oncol, 2009, 34(5):1303-1312.
[9]	Zhao J, Yu BY, Wang DY, et al. Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma[J]. World J Gastroenterol, 2010, 16(48):6104-6110.
[10]	Gao J. Association of MDR1 gene polymorphisms with the risk of hepatocellular carcinoma in the Chinese Han population[J]. Braz J Med Biol Res, 2013, 46(3):311-317.
[11]	Wang H, Li X, Chen T, et al. Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation[J]. Oncol Rep, 2013, 29(2):676-684.
[12]	Ye CG, Wu WK, Yeung JH, et al. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression[J]. Cancer Lett, 2011, 304(2):90-96.
[13]	Ye L, Zhao X, Lu J, et al. Knockdown of TIGAR by RNA interference induces apoptosis and autophagy in HepG2 hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun, 2013, 437(2):300-306.
[14]	Zeng XC, Zhang T, Huang DH, et al. RNA interfering targeting human leukocyte antigen-G enhanced immune surveillance mediated by the natural killer cells on hepatocellular carcinoma[J]. Ann Clin Lab Sci, 2013, 43(2):135-144.
[15]	Tepsiri N, Chaturat L, Sripa B, et al. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines[J]. World J Gastroenterol, 2005, 11(18):2748-2753.
[16]	Fallica B, Makin G, Zaman MH. Bioengineering approaches to study multidrug resistance in tumor cells[J]. Integr Biol, 2011, 3(5):529-539.

Please choose a citation manager

Content to export